- Home
- IRD vs MDCX Comparison
IRD vs MDCX Comparison
Compare IRD & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- MDCX
- Stock Information
- Founded
- IRD 2018
- MDCX 2008
- Country
- IRD United States
- MDCX Canada
- Employees
- IRD N/A
- MDCX N/A
- Industry
- IRD
- MDCX
- Sector
- IRD
- MDCX
- Exchange
- IRD NYSE
- MDCX Nasdaq
- Market Cap
- IRD 62.0M
- MDCX 44.0M
- IPO Year
- IRD N/A
- MDCX N/A
- Fundamental
- Price
- IRD $1.00
- MDCX $3.38
- Analyst Decision
- IRD Strong Buy
- MDCX Strong Buy
- Analyst Count
- IRD 3
- MDCX 2
- Target Price
- IRD $6.33
- MDCX $23.50
- AVG Volume (30 Days)
- IRD 795.7K
- MDCX 285.4K
- Earning Date
- IRD 08-15-2025
- MDCX 08-22-2025
- Dividend Yield
- IRD N/A
- MDCX N/A
- EPS Growth
- IRD N/A
- MDCX N/A
- EPS
- IRD N/A
- MDCX N/A
- Revenue
- IRD $13,651,000.00
- MDCX N/A
- Revenue This Year
- IRD $51.41
- MDCX N/A
- Revenue Next Year
- IRD $68.84
- MDCX N/A
- P/E Ratio
- IRD N/A
- MDCX N/A
- Revenue Growth
- IRD N/A
- MDCX N/A
- 52 Week Low
- IRD $0.65
- MDCX $1.80
- 52 Week High
- IRD $2.18
- MDCX $8.94
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- MDCX N/A
- Support Level
- IRD N/A
- MDCX N/A
- Resistance Level
- IRD N/A
- MDCX N/A
- Average True Range (ATR)
- IRD 0.00
- MDCX 0.00
- MACD
- IRD 0.00
- MDCX 0.00
- Stochastic Oscillator
- IRD 0.00
- MDCX 0.00
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.